v3.26.3
Condensed Combined and Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Balance (In shares), beginning at Dec. 31, 2024   61,507,446      
Balance beginning period at Dec. 31, 2024 $ 222,936 $ 6 $ 664,874 $ (3,356) $ (438,588)
Exercise of common stock options 14   14    
Exercise of common stock options, Shares   2,375      
Provision for pension benefit obligation 48     48  
Stock-based compensation expense 5,298   5,298    
Unrealized gain loss on available-for-sale securities (21)     (21)  
Net income (loss) 46,885       46,885
Balance end period at Mar. 31, 2025 275,160 $ 6 670,186 (3,329) (391,703)
Balance (In shares), period end at Mar. 31, 2025   61,509,821      
Balance (In shares), beginning at Dec. 31, 2024   61,507,446      
Balance beginning period at Dec. 31, 2024 222,936 $ 6 664,874 (3,356) (438,588)
Provision for pension benefit obligation 154        
Net income (loss) 7,509        
Balance end period at Sep. 30, 2025 245,837 $ 6 680,157 (3,247) (431,079)
Balance (In shares), period end at Sep. 30, 2025   61,790,239      
Balance (In shares), beginning at Dec. 31, 2024   61,507,446      
Balance beginning period at Dec. 31, 2024 222,936 $ 6 664,874 (3,356) (438,588)
Net income (loss) (38,600)        
Balance end period at Dec. 31, 2025 233,056 $ 7 714,090 (3,827) (477,214)
Balance (In shares), period end at Dec. 31, 2025   65,543,723      
Balance (In shares), beginning at Mar. 31, 2025   61,509,821      
Balance beginning period at Mar. 31, 2025 275,160 $ 6 670,186 (3,329) (391,703)
Restricted common stock vesting, Shares   112,159      
Provision for pension benefit obligation 53     53  
Stock-based compensation expense 4,894   4,894    
Unrealized gain loss on available-for-sale securities (97)     (97)  
Issuance of shares under employee stock purchase plan, Shares   95,369      
Issuance of shares under employee stock purchase plan 365   365    
Net income (loss) (12,295)       (12,295)
Balance end period at Jun. 30, 2025 268,080 $ 6 675,445 (3,373) (403,998)
Balance (In shares), period end at Jun. 30, 2025   61,717,349      
Exercise of common stock options 348   348    
Exercise of common stock options, Shares   72,890      
Provision for pension benefit obligation 53     53  
Stock-based compensation expense 4,364   4,364    
Unrealized loss on available-for-sale securities 73     73  
Net income (loss) (27,081)       (27,081)
Balance end period at Sep. 30, 2025 245,837 $ 6 680,157 (3,247) (431,079)
Balance (In shares), period end at Sep. 30, 2025   61,790,239      
Balance (In shares), beginning at Dec. 31, 2025   65,543,723      
Balance beginning period at Dec. 31, 2025 233,056 $ 7 714,090 (3,827) (477,214)
Restricted common stock vesting, Shares   186,515      
Exercise of pre-funded warrants   5,016,628      
Exercise of common stock options 4,522   4,522    
Exercise of common stock options, Shares   574,839      
Provision for pension benefit obligation 55     55  
Stock-based compensation expense 5,949   5,949    
Unrealized gain loss on available-for-sale securities (974)     (974)  
Issuance of common stock, Share   13,000,000      
Issuance of common stock 323,811 $ 1 323,810    
Net income (loss) (44,503)       (44,503)
Balance end period at Mar. 31, 2026 521,916 $ 8 1,048,371 (4,746) (521,717)
Balance (In shares), period end at Mar. 31, 2026   84,321,705      
Balance (In shares), beginning at Dec. 31, 2025   65,543,723      
Balance beginning period at Dec. 31, 2025 $ 233,056 $ 7 714,090 (3,827) (477,214)
Exercise of common stock options, Shares 1,008,520        
Provision for pension benefit obligation $ 161        
Net income (loss) (84,837)        
Balance end period at Sep. 30, 2026 496,208 $ 9 1,064,442 (6,192) (562,051)
Balance (In shares), period end at Sep. 30, 2026   85,431,211      
Balance (In shares), beginning at Mar. 31, 2026   84,321,705      
Balance beginning period at Mar. 31, 2026 521,916 $ 8 1,048,371 (4,746) (521,717)
Restricted common stock vesting, Shares   1,749      
Exercise of pre-funded warrants   509,300      
Exercise of pre-funded warrants, Amount   $ 1 (1)    
Exercise of common stock options 2,600   2,600    
Exercise of common stock options, Shares   346,713      
Provision for pension benefit obligation 54     54  
Stock-based compensation expense 5,970   5,970    
Unrealized gain loss on available-for-sale securities 473     (473)  
Issuance of shares under employee stock purchase plan, Shares   46,960      
Issuance of shares under employee stock purchase plan 611   611    
Net income (loss) (43,397)       (43,397)
Balance end period at Jun. 30, 2026 487,281 $ 9 1,057,551 (5,165) (565,114)
Balance (In shares), period end at Jun. 30, 2026   85,226,427      
Restricted common stock vesting, Shares   2,124      
Exercise of pre-funded warrants   115,692      
Exercise of common stock options 568   568    
Exercise of common stock options, Shares   86,968      
Provision for pension benefit obligation 52     52  
Stock-based compensation expense 6,323   6,323    
Unrealized gain loss on available-for-sale securities (1,079)     1,079  
Net income (loss) 3,063       3,063
Balance end period at Sep. 30, 2026 $ 496,208 $ 9 $ 1,064,442 $ (6,192) $ (562,051)
Balance (In shares), period end at Sep. 30, 2026   85,431,211